Evaluation of the Pharmacokinetics, Food Effect, Pharmacodynamics, and Tolerability of DA-1229, a Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers: First-in-Human Study

Clinical Therapeutics

Volumn 34, Issue 9, 2012, Pages 1986-1998

  Kim, Tae Eun ^a   Lim, Kyoung Soo ^a   Park, Min Kyu ^a   Yoon, Seo Hyun ^a   Cho, Joo Youn ^a   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

DA 1229; Pharmacodynamics; Pharmacokinetics; Tolerability

Indexed keywords

DA 1229; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGASTRIC DISCOMFORT; EROSION; FOOD; HEADACHE; HUMAN; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH MUCOSA EROSION; NOSE CONGESTION; PHARMACODYNAMICS; PHARYNGITIS; POSITIONAL DIZZINESS; PRODUCT DEVELOPMENT; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SOMNOLENCE; THROAT IRRITATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FOOD-DRUG INTERACTIONS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LINEAR MODELS; MALE; PIPERAZINES; REPUBLIC OF KOREA; YOUNG ADULT;

EID: 84866179930     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.08.006     Document Type: Article

References (21)

1. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009, 32(Suppl 1):S62-S67.
3. The Endocrine System. Robbins and Cotran Pathologic Basis of Disease 2005, Saunders, Philadelphia, PA. 7th ed. V. Kumar, N. Fausto, A.K. Abbas (Eds.).
4. Freeman J.S. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs. J Am Osteopath Assoc 2010, 110:528-537.
5. Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 2007, 21:517-533.
6. Kim M.K., Chae Y.N., Kim H.D., et al. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci 2012, 90:21-29.
7. Kim H.J., Kwak W.Y., Min J.P., et al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett 2011, 21:3809-3812.
8. Declaration of Helsinki: recommendations guiding medical doctors in biomedical research involving human subjects World Medical Association (WMA), Accessed 28 August, 2012. http://www.wma.net/en/30publications/10policies/b3/.
9. Guidline for Good Clinical Paractice International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Accessed 28 August, 2012. http://www.wma.net/en/30publications/10policies/b3/.
10. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications 2011, Lippincott Williams & Wilkins, Philadelphia, PA. 4th ed. M. Rowland, T.N. Tozer (Eds.).
11. Smith B.P., Vandenhende F.R., DeSante K.A., et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000, 17:1278-1283.
12. Goldenberg I., Moss A.J., Zareba W. QT interval: how to measure it and what is "normal.". J Cardiovasc Electrophysiol 2006, 17:333-336.
13. Scheen A.J. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010, 12:648-658.
14. Scheen A.J. A review of gliptins in 2011. Expert Opin Pharmacother 2012, 13:81-99.
15. Bloomfield D.M., Krishna R., Hreniuk D., et al. A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol 2009, 49:937-946.
16. Ring A., Port A., Graefe-Mody E.U., et al. The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. Br J Clin Pharmacol 2011, 72:39-50.
17. Qualmann C., Nauck M.A., Holst J.J., et al. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 1995, 32:13-16.
18. Ritzel R., Orskov C., Holst J.J., Nauck M.A. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995, 38:720-725.
19. Herman G.A., Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005, 78:675-688.
20. Lim K.S., Kim J.R., Choi Y.J., et al. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. Clin Ther 2008, 30:1817-1830.
21. Herman G.A., Zhao P.L., Dietrich B., et al. The DP-IV inhibitor MK-043 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetics. Diabetes 2004, 52(Suppl 2):A82. Abstract.